Advaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright
Advaxis, Inc. (NASDAQ:ADXS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Friday. They presently have a $23.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 378.17% from the stock’s current price.
Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald set a $19.00 price objective on Advaxis and gave the company a “buy” rating in a research note on Thursday, July 6th. BidaskClub upgraded Advaxis from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Finally, ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th.
Advaxis (NASDAQ:ADXS) traded down 2.43% during trading on Friday, reaching $4.81. 1,109,532 shares of the company were exchanged. The firm’s 50 day moving average price is $6.35 and its 200-day moving average price is $7.45. The stock’s market capitalization is $194.62 million. Advaxis has a one year low of $4.77 and a one year high of $12.66.
Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $3.43 million. On average, equities research analysts predict that Advaxis will post ($2.20) earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Stevens Capital Management LP bought a new stake in shares of Advaxis during the first quarter valued at about $105,000. Voya Investment Management LLC increased its position in shares of Advaxis by 20.3% during the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 2,975 shares during the period. Cutler Capital Management LLC bought a new stake in shares of Advaxis during the second quarter valued at about $130,000. American International Group Inc. increased its position in shares of Advaxis by 7.6% during the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 1,459 shares during the period. Finally, Northern Capital Management LLC increased its position in shares of Advaxis by 14.6% during the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 2,650 shares during the period. Hedge funds and other institutional investors own 48.78% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.